Autolus Therapeutics AUTL

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.06 (-2.90%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Autolus Therapeutics (AUTL)
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.01

  • Market Cap

    $534.90 Million

  • Price-Earnings Ratio

    -1.65

  • Total Outstanding Shares

    266.12 Million Shares

  • Total Employees

    463

  • Dividend

    No dividend

  • IPO Date

    June 22, 2018

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    American Depository Receipt Common

  • Headquarters

    The mediaworks, London, X0, W12 7FP

  • Homepage

    https://www.autolus.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-12.44 Million
Exchange Gains/Losses$47.73 Million
Net Cash Flow From Operating Activities, Continuing$-193.17 Million
Net Cash Flow From Operating Activities$-193.17 Million
Net Cash Flow From Financing Activities, Continuing$559.57 Million
Net Cash Flow From Investing Activities$-12.44 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-270.23 Million
Research and Development$145.15 Million
Operating Income/Loss$-218.83 Million
Preferred Stock Dividends And Other Adjustments$0
Basic Average Shares$251.53 Million
Income/Loss From Continuing Operations Before Tax$-270.19 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$-237.33 Million
Comprehensive Income/Loss$-237.33 Million
Comprehensive Income/Loss Attributable To Parent$-237.33 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Non-current Assets$65.12 Million
Current Assets$718.11 Million
Equity$476.96 Million
Noncurrent Liabilities$298.05 Million
Noncurrent Assets$109.38 Million
Liabilities And Equity$827.49 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AUTL from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.